Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2014 Jan 01;1711:253-64. doi: 10.1111/bph.12441.
Show Gene links
Show Anatomy links
G protein-gated inwardly rectifying potassium (KIR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites.
Nakamura A
,
Fujita M
,
Ono H
,
Hongo Y
,
Kanbara T
,
Ogawa K
,
Morioka Y
,
Nishiyori A
,
Shibasaki M
,
Mori T
,
Suzuki T
,
Sakaguchi G
,
Kato A
,
Hasegawa M
.
???displayArticle.abstract???
Oxycodone and morphine are μ-opioid receptor agonists prescribed to control moderate-to-severe pain. Previous studies suggested that these opioids exhibit different analgesic profiles. We hypothesized that distinct mechanisms mediate the differential effects of these two opioids and investigated the role of G protein-gated inwardly rectifying potassium (K(IR)3 also known as GIRK) channels in their antinociceptive effects. Opioid-induced antinociceptive effects were assessed in mice, using the tail-flick test, by i.c.v. and intrathecal (i.t.) administration of morphine and oxycodone, alone and following inhibition of K(IR)3.1 channels with tertiapin-Q (30 pmol per mouse, i.c.v. and i.t.) and K(IR)3.1-specific siRNA. The antinociceptive effects of oxycodone and morphine were also examined after tertiapin-Q administration in the mouse femurbone cancer and neuropathic pain models. The antinociceptive effects of oxycodone, after both i.c.v. and i.t. administrations, were markedly attenuated by K(IR)3.1 channel inhibition. In contrast, the antinociceptive effects of i.c.v. morphine were unaffected, whereas those induced by i.t. morphine were attenuated, by K(IR)3.1 channel inhibition. In the two chronic pain models, the antinociceptive effects of s.c. oxycodone, but not morphine, were inhibited by supraspinal administration of tertiapin-Q. These results demonstrate that K(IR)3.1 channels play a primary role in the antinociceptive effects of oxycodone, but not those of morphine, at supraspinal sites and suggest that supraspinal K(IR)3.1 channels are responsible for the unique analgesic profile of oxycodone.
Alexander,
The Concise Guide to PHARMACOLOGY 2013/14: overview.
2013, Pubmed
Alexander,
The Concise Guide to PHARMACOLOGY 2013/14: overview.
2013,
Pubmed
Bercovitch,
High dose controlled-release oxycodone in hospice care.
2006,
Pubmed
Boström,
In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics.
2006,
Pubmed
Boström,
Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine.
2008,
Pubmed
Chang,
Dissociation of opioid receptor upregulation and functional supersensitivity.
1991,
Pubmed
Cruz,
Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice.
2008,
Pubmed
Heiskanen,
Controlled-release oxycodone and morphine in cancer related pain.
1997,
Pubmed
Hoehn,
Pertussis toxin inhibits antinociception produced by intrathecal injection of morphine, noradrenaline and baclofen.
1988,
Pubmed
Honore,
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord.
2000,
Pubmed
Ikeda,
Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia.
2000,
Pubmed
Jin,
A novel high-affinity inhibitor for inward-rectifier K+ channels.
1998,
Pubmed
,
Xenbase
Kilkenny,
Animal research: reporting in vivo experiments: the ARRIVE guidelines.
2010,
Pubmed
Klimas,
Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.
2013,
Pubmed
Komiya,
Bone tumors in the pelvis presenting growth during pregnancy.
1999,
Pubmed
Koyyalagunta,
A systematic review of randomized trials on the effectiveness of opioids for cancer pain.
2012,
Pubmed
Lemberg,
Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
2006,
Pubmed
Malmberg,
Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates.
1998,
Pubmed
Marker,
Hyperalgesia and blunted morphine analgesia in G protein-gated potassium channel subunit knockout mice.
2002,
Pubmed
Marker,
Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia.
2004,
Pubmed
McGrath,
Guidelines for reporting experiments involving animals: the ARRIVE guidelines.
2010,
Pubmed
Mercadante,
Breakthrough pain in cancer patients: pathophysiology and treatment.
1998,
Pubmed
Minami,
Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models.
2009,
Pubmed
Mitrovic,
Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences.
2003,
Pubmed
Moulin,
Randomised trial of oral morphine for chronic non-cancer pain.
1996,
Pubmed
Nakamura,
Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model.
2013,
Pubmed
Narita,
Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine.
2008,
Pubmed
Pandit-Taskar,
Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
2004,
Pubmed
Peckham,
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
2006,
Pubmed
Portenoy,
Breakthrough pain: characteristics and impact in patients with cancer pain.
1999,
Pubmed
Seltzer,
A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury.
1990,
Pubmed
Shah,
Time-dependent effects of in vivo pertussis toxin on morphine analgesia and G-proteins in mice.
1997,
Pubmed
Silvestri,
Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.
2008,
Pubmed
Tunblad,
Morphine blood-brain barrier transport is influenced by probenecid co-administration.
2003,
Pubmed
Vaughan,
How opioids inhibit GABA-mediated neurotransmission.
1997,
Pubmed
Watson,
Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.
1998,
Pubmed
Yoshimura,
Substantia gelatinosa neurones hyperpolarized in vitro by enkephalin.
,
Pubmed
Yow,
Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapin-Q.
2011,
Pubmed
,
Xenbase